Pharmacogenomics and personalised medicine are increasingly becoming a part of mainstream healthcare and it is an area where pharmacists have a major part to play. In this series of short videos, Raliat Onatade, Chief Pharmacist for North Thames Genomic Medicines Service Alliance, describes what has already been done and the opportunities and challenges for further development. The added value of […]
Recent research has demonstrated the value of pharmacogenomics-guided prescribing but this is a far cry from the implementation of routine services. Dr Raliate Onatade Chief Pharmacist for North Thames Genomics Medicine Service Alliance, explains what is required and the challenges that need to be addressed. [embedded content] The PREPARE (PREemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions) study assessed the […]
A number of examples show how pharmacogenetic testing is being integrated into day-to-day practice and helping to improve the safe and effective use of medicines, Raliat Onatade, Chief Pharmacist for North Thames Genomics Medicine Service Alliance, explains. [embedded content] Mitochondrial mutation The mitochondrial mutation m.1555A>G is often associated with maternally-transmitted deafness. People who carry this mutation are more likely to […]
Raliat Onatade, Chief Pharmacist for North Thames Genomic Medicines Service Alliance, recently gave the opening keynote address at the EAHP Congress in Lisbon (March 2023) on the subject of pharmacogenomics and personalised medicine. IMI spoke to her to find out more about the topic and the opportunities that it offers to hospital pharmacists in clinical practice. [embedded content] Dr Onatade’s […]
Merck Inc., known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor antagonist, developed for the treatment for adults with refractory or unexplained chronic cough. The CHMP’s recommendation will now be […]
Frontline treatment with the combination of nivolumab (Opdivo) and cisplatin-based chemotherapy, followed by nivolumab monotherapy, led to a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) compared with standard cisplatin-based chemotherapy regimens alone in previously untreated, cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma, according to data from the phase III CheckMate-901 trial (NCT03036098). The study met […]
Renalytix plc announces that the FDA has granted De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic (diabetic) kidney disease. Renalytix believes FDA authorization will lead to increasing test adoption, informing clinical guidelines, expanding insurance […]
Biotronik announced FDA approval of its portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy pacemaker (CRT-P), its latest innovation in cardiac rhythm management. Amvia Edge, the market’s smallest single-chamber MR conditional pacemaker, introduces a unique set of patient-centric clinical solutions coupled with automated workflow efficiency. Amvia Edge pacemakers feature Biotronik’s proprietary MRI Guard 24/7 technology, which uses always-on, dedicated […]
Taiho Pharmaceutical and its subsidiary Taiho Oncology Europe have received conditional marketing authorisation from the European Commission for Lytgobi (futibatinib) tablets to treat adults with cholangiocarcinoma (CCA). The authorisation is based on the data from the global, open label FOENIX-CCA2 trial. It enrolled a total of 103 adult patients from the Netherlands, UK, Spain, Italy, France, and Germany. Patients with […]
Incyte announced positive topline results from its randomized, vehicle-controlled, pivotal Phase III TRuE-AD3 study evaluating the safety and efficacy of Opzelura (ruxolitinib cream) in children (age at least 2 to <12 years) with atopic dermatitis (AD). The study met its primary endpoint and showed significantly more patients treated with ruxolitinib cream 0.75% and 1.5% achieved Investigator’s Global Assessment Treatment Success […]
Recent Comments